Skip to main content

Table 2 Main characteristics of patients enrolled among trials included in the meta-analysis

From: Association of statin use and clinical outcomes in heart failure patients: a systematic review and meta-analysis

Study, year

Arms

No

EF %

Age Year

BMI

Male %

DM %

HTN %

Smoking %

TC mmol/L

Triglyceride mmol/L

Horwich et al. 2004

S

C

200

250

≤40%

≤40%

57 ± 11

48 ± 13

28.2 ± 6.2

26.9 ± 6.2

82

70

33

16

64

43

80

66

4.32 ± 1.25

4.2 ± 1.5

1.87 ± 1.3

1.98 ± 2.17

Sola et al. 2005

S

C

225

191

≤35%

≤35%

55.4 ± 6.4

53.8.4 ± 5.7

24.3 ± 3.8

23.5 ± 4.3

62

63

24

27

41

36

34

30

NR

NR

2.8 ± 0.5

2.9 ± 0.4

Fukuta et al. 2005

S

C

69

68

≥50%

≥50%

65 ± 2

65 ± 16

NR

NR

51

45

34

12

87

72

NR

NR

6.07 ± 2.22

4.67 ± 1

2.31 ± 2.21

1.64 ± 0.90

Hong et al. 2005

S

C

106

96

≤40%

≤40%

61.8 ± 10.3

60.9 ± 10.4

NR

NR

72

75

32

28

41

44

57

52

NR

NR

NR

NR

Go et al. 2006

S

C

12,648

11,950

≤40%

≤40%

69.6 ± 10.3

72.9 ± 11.4

NR

NR

62

60

55.7

41.3

89

83

NR

NR

5.37 ± 1.14

5.68 ± 1.22

NR

NR

Kjekshus et al. 2007

S

C

2514

2497

≤40%

≤40%

73 ± 7.1

73 ± 7.0

27 ± 4.5

27 ± 4.6

76

76

30

29

63

63

9

8

5.36 ± 1.11

5.35 ± 1.06

2.01 ± 1.33

1.99 ± 1.23

Huan et al. 2007

S

C

377

102

≤40%

≤40%

74 ± 4

74 ± 3

26.5

28.1

66

77

NR

NR

NR

NR

75

72

5.1 ± 0.25

5.5 ± 0.3

NR

NR

Coleman et al. 2008

S

C

642

562

≤30%

≤30%

67.5 ± 13

64.5 ± 10.8

NR

NR

80.7

76.2

31.5

30.2

43.8

34.9

NR

NR

NR

NR

NR

NR

Roik et al. 2008

S

C

103

43

≥45%

≥45%

69 ± 11

66 ± 16

28.6 ± 4.8

27.2 ± 4.9

50.5

58

25

12

76

58

43

34

4.57 ± 1.37

4.57 ± 1.03

1.64 ± 1.08

1.62 ± 1.05

Tavazzi et al. 2008 the GISSI-HF trial

S

C

2285

2289

33.4

33.4

68 ± 1

68 ± 1

27·1 ± 4.6

27.71 ± 4.4

78.6

76.8

25

27.4

53.5

55.1

14.1

14

NR

NR

NR

NR

Gomez-Soto et al. 2010

S

C

1343

1230

≥47%

≥47%

71.5 ± 6.9

69.8 ± 7.8

NR

NR

51.6

43.9

36.8

47.7

45.6

48.5

33

31

NR

NR

NR

NR

Kaneko et al. 2013

S

C

459

665

≥50%

≥50%

65.6 ± 11.7*

24.3 ± 3.6*

76.2*

32.4*

64.5*

24.2*

NR

NR

NR

NR

Yap et al. 2015

S

C

457

293

≥50%

≥50%

73.1 ± 10.6*

26.5*

35.3*

47.1*

80.3*

NR

NR

NR

NR

NR

NR

Nochioka et al. 2015

S

C

1163

1961

≥50%

≥50%

69.0 ± 11.0

69.7 ± 12.9

67.5

64

45

40.8

33.8

20.9

85

76.7

45

40.8

NR

NR

1.51 ± 0.82

1.4 ± 0.81

Alehagen U et al.

2015

S

C

3427

5713

≥50%

≥50%

78 ± 12

75 ± 9

29 ± 6

27 ± 6

54

42

31

28

62

64

NR

NR

NR

NR

NR

NR

Alehagen et al. 2015

S

C

10,345

11,519

< 40%

< 40%

72 10

72 ± 14

27 ± 5

26 ± 5

75

68

33

18

48

39

41

49

NR

NR

NR

NR

Tsujimoto et al. 2018

S

C

1765

1613

≥50%

≥50%

69 ± 9.6

68.1 ± 9.6

NR

NR

55

42

42.9

20.8

93.1

89.8

10.5

10.6

NR

NR

NR

NR

  1. Abbreviations: S: statins; C: control; HTN: hypertension; DM: diabetes mellitus; TC: total cholesterol; EF: ejection fraction; NR: not-reported; *: only whole group represented